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Interleukin 2  (IL-2) 1 was discovered through its function as a T  cell growth 
factor (TCGF) (1, 2).  Indeed, the availability of T  cell lines for the quantitative 
measurement of TCGF activity has been crucial for the characterization of IL-2 
(3, 4) and IL-2 receptors on activated T  cells (5-7) in different species. Human 
IL-2,  which acts on  murine and human T  cells (4,  8,  9),  can now rapidly be 
purified  to  apparent  homogeneity with  monoclonal  antibodies  (8,  9)  and  its 
cDNA has been cloned (10, 11). Human I L-2 is a T  ceil-generated 15 kilodalton 
peptide hormone of 133 amino acids. 
Although it was observed in several studies (3, 4,  12-14) that IL-2-rich T  cell 
supernatants  (SN)  enhance  the  generation  of plaque-forming  cells  (PFC)  in 
certain B cell culture systems, it is widely believed that B cells do not directly 
respond to IL-2. Thus, a variety of other T  cell-derived factors (but not IL-2) 
were reported  to  enhance the proliferation  of B  cells activated by either T- 
independent  antigens  (15),  dextran  (16),  lipopolysaccharide  (LPS)  (17,  18), 
antiimmunoglobulin antibodies (anti-Ig) (16,  19-21),  or other means (22).  In 
one study (23),  showing an effect of immunoaffinity-purified IL-2 on anti-Ig- 
induced B cell proliferation, the interpretation of the results was complicated 
because it was also observed that T  cells participated in the B cell response. LPS- 
activated murine B cells were not found to bind radiolabeled IL-2  (5)  but,  in 
another study (7),  such  LPS  blasts  reacted weakly with an anti-IL-2 receptor 
monoclonal antibody. 
However, there still  exist controversies with regard to the activation signals 
that B cells require to respond to growth factors (24). A recent study (25) showed 
in a  limit-dilution culture system for murine B cells that,  in  fact, either a  cell 
contact-dependent T-B cell interaction or LPS was required in conjunction with 
anti-Ig for optimal induction of growth factor responsiveness. Whereas anti-Ig 
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alone had no significant effect,  B  cells activated by  LPS and anti-Ig together 
proliferated 10-fold better in response to T  cell SN than B cells activated by LPS 
alone (25).  Those  results suggest that some previously reported  B  cell growth 
factors  (BCGF)  could  have  (directly  or  via  other  cells)  participated  in  B  cell 
activation  but  may  be  different  from  the  essential  growth  factors  acting  on 
activated B cells. 
In this study it was investigated whether IL-2 acts on B cell proliferation and 
whether activated B  cells express IL-2 receptors.  The results demonstrated (a) 
that either recombinant or immunoaffinity-purified human IL-2 stimulated the 
proliferation of LPS plus anti-Ig-activated purified murine B cells to the same 
extent as various T  cell and spleen cell SN, (b) that very similar IL-2 concentra- 
tions were required for B vs. T  cell proliferation, and (c) that LPS plus anti-Ig- 
activated B cells expressed IL-2 receptors. 
Materials and Methods 
Mitogens, Anti-Ig Antibodies.  LPS (Westphal) from Eschericha coli 055:B5 was obtained 
from Difco Laboratories, Inc., Detroit, MI. Concanavalin A (Con A), phytohemagglutinin 
(PHA),  and  leukoagglutinin were  obtained  from  Pharmacia,  Inc.,  Uppsala,  Sweden. 
Affinity-purified (on mouse Ig-Sepharose) rabbit anti-mouse Ig antibodies were prepared 
from hyperimmune polyvalent rabbit anti-mouse Ig antiserum and coupled to cyanogen 
bromide-activated Sepharose 4B (Pharmacia, Inc.) at Img protein/ml of packed beads 
as described (25). 
Culture Media,  General Culture Methods.  Cell cultures were performed in Dulbecco's 
modified Eagle's medium (DME) supplemented with additional amino acids and including 
10 mM Hepes, penicillin-streptomycin, and 5 x  10  -5 M 2-mercaptoethanol (26). Fetal calf 
serum (FCS)  (lot  106183)  was obtained from Seromed, Munich, Federal  Republic of 
Germany. Cultures of 1 ml were performed in 24-well plates, cultures of 200 or 150 ~1 
cultures in 96-well flat-bottomed plates (Costar, Data Packaging, Cambridge, MA). 
Preparation  and Immunohistochemical Analysis  of B Cells.  Surface Ig (sIg)-positive cells 
were obtained from C57BL/6 spleen cells by the panning method of Mage et al. (27). 
The efficiency of this method was checked by the quantitation of sIg  + and Thy-1 ÷ cells 
on acetone-fixed cytocentrifuge smears using biotinylated horse anti-mouse Ig antibody 
(Vector Laboratories, Inc., Burlingame, CA) or biotinylated monoclonal anti-Thy-1 anti- 
body (AT-15,  provided by Dr.  F.  Fitch, University of Chicago) together with avidin- 
peroxidase conjugate (Vector Laboratories, Inc.) and hematoxylin counterstaining. 3,000 
cells were scored. Freshly prepared B cells contained >97% sIg  + cells and <0.3% Thy-1 ÷ 
cells. Control cells (Con A-stimulated thymocytes) were >98% Thy-1 +. In addition, it was 
found that B cells cultured during 4 d in the presence of LPS, anti-Ig, and EL-4 SN (see 
below) contained >99% Ig-positive  cells and <0.2% Thy-1 + cells. 
Murine B Blast Assay for B Cell Growth Factor.  To obtain activated B cells, 3 x  10 ~  sIg  + 
cells were cultured during 3 d in 1-ml cultures in the presence of 5 #g/ml of LPS, 10 #g/ 
ml of Sepharose-anti-mouse Ig, and 10% FCS, followed by removal of anti-Ig beads from 
the culture suspension by sedimentation (10 min at 1 g), centrifugation of the cells, and 
resuspension in  fresh  DME.  Assay  cultures  (150  /zl, triplicates) were  set  up  with  104 
activated B cells, 10% FCS, and dilutions of tested supernatants. Thymidine incorporation 
was measured 3 d later (by standard procedure, using an automated cell harvester), after 
a  6-h pulse with  1 #Ci of [3H]thymidine (Radiochemical Centre, Amersham, England) 
added in 50 ~1 of DME. 
PFC Assay. PFC  were  measured  using protein  A  (Pharmacia,  Inc.)-coupled  sheep 
erythrocytes (29) and a slide modification of the plaque assay (30) as described (26). 
Analysis  and Separation  of Cells with  the  Fluorescence-activated Cell Sorter  (FACS).  A 
FACS II (Beckton, Dickinson & Co., Mountain View, CA) was used in conjunction with 1172  INTERLEUKIN 2  IS  A  B CELL  GROWTH  FACTOR 
monoclonal anti-Thy-I and anti-Lyt-2 antibodies coupled to biotin, with fluoresceinated 
avidin as a second reagent as described (31, 32). 
IL-2 Assay  Using  CTLL  Cells.  IL-2  biologic  activity  was  determined  by  the  IL-2- 
dependent stimulation of proliferation of the CTLL-2 murine cytotoxic T  lymphocyte 
line (8). CTLL cells (4 x  10S/culture of 200 #1) were cultured during 24 h, in the presence 
of DME-5% FCS and serial dilutions of tested SN. During the last 5 h, the cultures were 
pulsed with  1  #Ci of [SH]thymidine.  The  IL-2 concentration  leading to 50%  maximal 
thymidine incorporation was assigned a value of 1 U/ml. Thus a sample containing  100 
U IL-2/ml would give 50% maximal stimulation at a  dilution of 1:100 in the assay. 
Immunoaffinity-purif~ed  Human IL-2.  IL-2-containing SN  were obtained from a  sub- 
clone (6.8  b) of the  IL-2 high-producer Jurkat  6.8  human  T  leukemia cell line in the 
absence of serum and the IL-2 purified on an immunosorbent column as described (8). 
Affi-gel 10 beads coupled with DMS-3 monocional anti-IL-2 antibodies were provided by 
Dr. K. A. Smith, Dartmouth, NH. The specific activity of the affinity-purified IL-2 was 1 
U  (see CTLL assay) per 0.3  ng protein.  A  single stained  band of 15,000  tool wt was 
obtained by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). 
Recombinant human IL-2.  The construction, cloning, and screening of a human IL-2 
cDNA plasmid made from polyadenylated RNA isolated from PHA-stimulated human 
spleen cells and its expression in E. eoli has been described (11). E. coli-derived  recombinant 
IL-2 was purified to apparent homogeneity according to SDS-PAGE and freed of endo- 
toxin  (methods  from  Biogen  SA,  Geneva,  Switzerland).  The  specific  activity  of the 
recombinant IL-2 was also 1 U/0.3 ng protein. 
[SH]IL-2-binding Assay.  Biosynthetically radiolabeled IL-2 was prepared (5).  Briefly, 
Jurkat cells were cultured in the presence of DME with 40 #M leucine and lysine (i.e., 5% 
of the levels in regular DME) and  10 mCi of both [SH]leucine (160 Ci/mM; Amersham 
Corp., Arlington Heights, IL) and [nH]iysine  (85 Ci/mM; Amersham Corp.). ~ The radio- 
labeled IL-2 was immunoaffinity purified (8), tested for biological activity, and adjusted 
to 500 cpm/U IL-2 (25,000 cpm/pmol). The cell-binding assay was performed as described 
by Robbet al. (5).  The LPS plus anti-Ig-activated B cells to be tested were obtained as 
follows. Cultures (250 #1) were set up with 3 x  104 C57BL/6 sIg  + cells, 50 #g/ml LPS, 10 
#g/ml Sepharose-anti-Ig, and 20%  EL-4 SN  (see below) in  DME-10%  FCS (using four 
complete 96-well plates). After 4 d, the cells were harvested and the anti-Ig beads removed, 
first by sedimentation (10 min at 1 g), and the remaining beads (~5%) by centrifugation 
(10 rain at 850 g) of the cells (15 x  106 cells in 5 ml DME) on top of Ficoll (3 ml, density 
1.077;  Seromed) in 10-ml tubes. By microscopic counting it was found that all beads and 
also the dead cells sedimented to the bottom of the tubes whereas the activated B cells 
remained at the interface. The B cells had multiplied  10  times during the  4-d culture 
period and 75% of the viable cells were recovered after the sedimentation and centrif- 
ugation on Ficoll.  LPS-activated B cells were obtained in the same way, i.e., the cultures 
also included 20% EL-4 SN. Con A-activated T  cells were obtained by culturing C57BL/ 
6 spleen cells during 4 d in the presence of 1 •g/ml  Con A and 20% EL-4 SN in DME- 
5% FCS. Before the binding assay, all cells were washed three times in DME and incubated 
for 2 h at 37°C to promote the removal of cell-bound IL-2. Aliquots of 5 x  106 cells (in 
200 #1 DME) were incubated in the presence of [SH]IL-2 for 20 rain at 37°C, after which 
time 800 #1 of cold DME was added.  Free and cell-bound [SH]IL-2 was determined as 
described (5). 
Cell SN.  Culture  SN  was obtained from various types of cells  as described  below, 
filtered  (0.22  t~m), and  the  IL-2  concentration  measured  in  parallel  with  the  BCGF 
activity. (a) PHA-stimulated human spleen cell SN (H-PHA SN) (144 U IL-2/mi): Mono- 
nuclear spleen cells (5 X 106/ml) were cultured during 36 h in the presence of 1% PHA 
and 2% human serum. The SN was concentrated two times by fractionated (NH4)2 SO4 
precipitation, i.e., the material soluble at 40% saturation was precipitated at 80% satura- 
tion followed by dialysis against RPMI (33).  PHA SN  was provided by Dr.  L. Moretta, 
Lowenthal, J.  W.,  C.  Tougne,  H.  R.  MacDonald, K. A. Smith, and  M.  Nabholz. Antigenic 
stimulation regulates the expression oflL-2 receptors by a cytolytic T cell clone. Manuscript submitted 
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Epalinges.  (b) Con A-stimulated murine spleen  cell SN (Con  A SN) (540 U  IL-2/ml): 
CBA spleen cells (106/ml) were cultured during 24 h in the presence of 4 #g/ml of Con 
A  and  5%  FCS.  (c) Murine (BALB/c anti-DBA/2) secondary in  vitro mixed leukocyte 
culture SN (MLC SN) (474 U IL-2/ml) was prepared as described (34). (d) EL-4 SN (600 
U IL-2/ml):  EL-4 thymoma cells (106/ml) were cultured during 40 h in the presence of 
10 ng/ml of phorbol- 12-myristate-13-acetate  and 2% FCS (28). Different batches of SN 
were adjusted to 600 U IL-2/ml by 2-4-fold dilution in DME-2% FCS. (e) Murine cloned 
T helper cell SN (TH-HY 6 SN) (180 U IL-2/ml):  H-Y-specific cloned T helper cells (26) 
(106/ml) were cultured during 24 h in the presence of 4 #g/ml of Con A and 5% FCS. 
(f) Murine T  cell hybridoma SN (FS6 SN, 216 U IL-2/ml; AOFS SN, 366 U IL-2/ml): 
FS6-14.13 cells (106/ml) or AOFS21 cells (5 ×  105/ml) (35) were cultured during 24 h in 
the presence of 2 #g/ml of Con A and 2% FCS. The FS6 SN was concentrated 10 times 
by fractionated (NH4)2 SO4 precipitation as described above for PHA SN. The hybrido- 
mas, originally obtained from Dr. P. Marrack and Dr. J. Kappler,  Denver, were provided 
by Dr. J. P. Corradin,  Epalinges.  (g) P388D~ SN (no IL-2 activity): SN from ultraviolet 
light-stimulated P388DI cells (36) with potent IL-1 activity in a thymocyte proliferation 
assay was provided by Dr. J. Louis and Dr. R. Titus, Epalinges. 
Results 
Murine B Blast Assay for B Cell Growth Factor.  In a recent report (25) by one 
of us  it  was  shown  that  LPS  and  polyvalent  rabbit  anti-mouse  Ig  antibodies 
coupled  to  Sepharose  beads (anti-Ig)  together  induced  optimal  growth  factor 
responsiveness of murine  B cells in a  T  cell-depleted polyclonal B cell system. 
Based  on  these  results,  a  quantitative  B  blast  assay for  BCGF  has  now  been 
developed. To obtain activated B cells, positively selected sIg  + cells were cultured 
(3 ×  105/ml) during 3 d  in the presence of anti-Ig (10 #g/ml) and LPS, followed 
by one cell wash and depletion of anti-Ig beads by sedimentation. A concentration 
of 5  #g/ml  of LPS  was  found  to  be  optimal  with  regard  to  the  subsequent 
detection of BCGF. On day 3,  the B cells had  multiplied by a  mean  2.5 times 
and become >90% large ceils according to FACS analysis. To further establish 
the optimal assay conditions, cultures (150 #1) were set up with different numbers 
of activated B cells suspended  in fresh medium-10%  FCS-10%  EL-4 SN as a 
source of T  cell factors (or control cultures  without SN).  3  d  later,  thymidine 
incorporation was measured, after a 6-h pulse (see Fig.  1A). The highest stimu- 
lation  index  (cpm  per  test  culture/cpm  per  control  culture)  was  obtained  in 
cultures with  104 activated B cells. This cell number was thus routinely used. It 
was also found in cultures with  104 B cells that the stimulation index was lower 
when thymidine incorporation was measured either on day 2 (because of a higher 
control response) or on day 4  (because of overgrowth of the cultures, data not 
shown).  In  confirmation  of the  immunohistochemical  analysis  of B  cells  (see 
Materials and  Methods),  T  cells, i.e.,  Thy-1 + cells,  were not detectable by the 
FACS in either the starting or the LPS/anti-Ig-activated  B cell populations (not 
shown) or in the cell population recovered after the  3-d cultures performed in 
the presence of EL-4 SN (see Fig.  1 B). 
Effects of  lL-2 and Various  T Cell SN in the B Blast Assay.  Dose-response curves 
for  the  effects of IL-2  and  different  sources  of T  cell  factors  on  thymidine 
incorporation in the B blast assay are shown in Fig. 2. Human IL-2, purified to 
apparent homogeneity according to SDS-PAGE analysis, was obtained either by 
immunoaffinity purification of IL-2 generated by Jurkat cells or by biochemical 
purification  of recombinant  IL-2 generated  by E.  coli (see Materials and  Meth- 1174  INTERLEUK1N  2  IS  A  B CELL  GROWTH  FACTOR 
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FIGURE 1.  (A) Relationship between thymidine incorporation  and the number of activated 
B cells added per culture in the murine B blast assay. Cultures (150 ~1) with 10% EL-4 SN (O) 
or control cultures without SN (O) were set up with different numbers of sIg  + cells that had 
been precultured  during 3 d in the presence of LPS (5/~g/ml) and Sepharose-coupled anti-Ig 
(10 #g/ml).  Thymidine  incorporation  was measured  3 d  later.  The figure  shows cpm per 
culture (y axis) vs. number of B cells per culture (x axis). In addition, stimulation indices (cpm 
per culture with SN/cpm per control culture) are indicated by numbers. (B) Absence of Thy- 
1-positive cells at the time of thymidine addition in the B blast assay. For the FACS analysis, 
the cultured B cells were harvested and either treated with biotinylated monoclonal anti-Thy- 
1 antibody and fluoresceinated avidin (--) or fluoresceinated avidin alone (---). EL-4 cells 
were used as the positive control. The fluorescence profiles were plotted by a computer using 
arbitrary linear scales for fluoresence intensity (x axis) and cell number (y axis). 
ods). It was found that either affinity-purified or recombinant IL-2 supported B 
cell proliferation as well as (or better than)  lectin-stimulated  murine  or human 
total spleen  cell SN,  murine  MLC  SN,  or SN  obtained  from murine  cloned  T 
helper cells (TH-HY6) (25) and T  cell hybridomas (FS6 and AOFS) (13,  14,  23, 
35). TH-HY6 provide themselves, in conjunction with anti-Ig, all signals required 
by B cells for a  PFC response (25). Moreover, as can be seen in Fig. 2, there was 
a  striking correlation between the IL-2 activity of different T  cell SN and their 
activity in  supporting  B  cell  proliferation.  Only  some  batches  of EL  SN  (e.g., 
batch  22)  but  not  others  (e.g.,  batch  25)  led  to  a  two-  to  threefold  higher 
maximum proliferative response than IL-2. It is not known whether this variation 
was due to the presence of other growth factors (19) or phorbol ester in certain 
batches of EL-4 SN. Finally, the SN from the monocytic cell line P388D1,  which 
had a  high  IL-1 activity in a  thymocyte proliferation assay (not shown) and was 
previously found  (24)  to  strongly enhance  T  cell-dependent  B  cell  activation, 
had  absolutely  no  effect  in  the  B  blast  assay  when  tested  either  alone  or  in 
conjunction with IL-2. 
As  shown  in  Fig.  3,  the  capacity  of either  recombinant  IL-2,  EL-4  SN,  or 
murine  MLC  SN  to  support  the  generation  of protein  A-PFC  in  the  B  blast 
assay correlated with the capacity to support proliferation; i.e., the relationship 
between proliferation and differentiation  into PFC was the same with different 
sources of T  cell factors in this assay. ZUBLER ET AL.  1175 
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FIGURE 2.  Correlation between IL-2 concentration and proliferation in the murine B blast 
assay: effect on thymidine incorporation of affinity-purified (P) or recombinant (R) human IL- 
2 or different cell supernatants: EL-4 SN (batch 22 and batch 25); murine MLC SN (M-MLC); 
Con A-stimulated murine spleen cell SN (M-CONA); murine T  cell hybridoma SN (AOFS 
and FS6); murine cloned T  helper cell SN (TH-HY6); PHA-stimulated human spleen cell SN 
(H-PHA); P388Dt SN (P388). The SN concentration is expressed in units IL-2/ml, according 
to the activity in the CTLL assay.  The highest SN concentration corresponded to 33% SN in 
the  B  blast  assay,  except  for  P388D]  SN,  which  was  tested  at  3%.  Two  representative 
experiments are shown.  The dotted lines indicate cpm per control culture (104 activated B 
cells). 
Comparison  of lL-2 Requirements for the Proliferation  of T Cells vs. B Cells.  1 U 
of  IL-2/ml  was  defined  as  the  IL-2  concentration  leading  to  50%  maximal 
thymidine  incorporation  in  the  24-h  assay  using  CTLL-2  cells.  However,  to 
compare the IL-2 requirements for the proliferation of normal, polyclonal T  vs. 
B cell populations, a recently developed thymidine incorporation assay was used. 3 
Cultures (200 pl) were set up with 2 x  103 FACS-selected Lyt-2  ÷ (murine) splenic 
T  cells, leukoagglutinin, and dilutions of recombinant human IL-2. As shown in 
Fig.  4,  the  concentration  of IL-2  required  in  this  system  for  50%  maximal 
thymidine incorporation  on  day  3  of culture  (6  U/ml)  was  identical with  that 
required in the B blast assay.  Moreover, it appears that an increase from 80 to 
160 U  IL-2/ml still led to an increased proliferative response when the thymidine 
incorporation  was  measured  on day  5.  A  similar  requirement for a  high  IL-2 
concentration was found for B cell proliferation in cultures with 104 B cells, LPS, 
and anti-Ig that lasted 5 d  (data not shown). 
Specific Binding of Radiolabeled IL-2 to LPS plus Anti-Ig-activated B Cells.  Using 
3 Erard,  F.,  P.  Corthesy, M.  Nabholz, J.  W.  Lowenthal, P.  Zaech, G.  Plaetinck, and  H.  R. 
MacDonald. Interleukin  2 is both  necessary and sufficient for the growth and differentiation of 
lectin-stimulated cytolytic T lymphocyte precursors. Manuscript submitted for publication. 1176  INTERLEUKIN  2  IS  A  B  CELL  GROWTH  FACTOR 
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FIGURE 4.  Effect of recombinant I L-2 on T  cell proliferation. Cultures (200 .t) were set up 
with 2 x  10 s Lyt-2-positive (murine) splenic T cells (obtained by the FAGS; 2% Lyt-2-negative 
cells),  leukoagglutinin (0.5 #g/ml), and ILo2, at the concentrations indicated in the figure. 
Thymidine incorporation was measured on either day 3 (&), 4 (•), or 5 (11) of culture, after a 
5-h pulse with  1 uCi of [SH]thymidine. The dotted line indicates cpm/culture in the absence 
of IL-2 (day 5). 
a  radiolabeled  IL-2 binding assay,  Robb  et al. (5) could detect IL-2 receptors on 
activated  murine  and  human  T  cells quantitatively and  measure  their  affinity. ZUBLER ET  AL. 
TABLE  I 
[3H]IL-2 Binding to LPS plus Antidg-activated B Cells vs. Con A- 
activated  T Cells 
1177 
Cells  [SH]IL-2  [SH]IL-2  +  Inhibition  cold IL-2 
epm  cpm  % 
Nonactivated B cells  45  ND 
LPS/anti-Ig-activated B cells  1,520  120  92 
Con A-activated T cells  4,770  640  87 
5 ×  106 cells were incubated for 20 rain at 37°C with radiolabeled IL-2 alone 
(25,000 cpm; see Materials and Methods) or together with a 50-fold excess of 
unlabeled IL-2; bound cpm were determined after subtraction of the machine 
background (55 cpm). 
But these authors did not detect IL-2 receptors on LPS-activated murine B cells. 
In view of the results shown above, we performed this assay with B cells activated 
with  LPS and anti-Ig for 4  d  in  the presence  of EL-4  SN  (LPS plus anti-Ig- 
activated  B  cells).  Nonactivated  B  cells  or  B  cells cultured during 4  d  in  the 
presence of LPS and EL-4 SN but not anti-Ig (LPS-activated B cells) were also 
tested. Since B cells cultured in the presence of anti-Ig and EL-4 SN alone died 
rapidly (24), such cells could not be analyzed. 
By using immunoaffinity-purified [SH]IL-2 at a  concentration that was satu- 
rating for T  cells,  ~ we found (see Table I) (a) that LPS plus anti-Ig-activated B 
cells bound [SH]IL-2 in a specific, coid-competable manner, (b) that the amount 
of [SH]IL-2 specifically bound by such activated B cells at equilibrium was, on a 
per cell basis, one-third of that bound by Con A-activated T  cells, and (c) that 
nonactivated  B  cells  (i.e.,  freshly prepared  sIg  +  cells)  did  not  bind  [3H]IL-2. 
Although anti-Ig beads were  not detected by microscopic examination of LPS 
plus anti-Ig-activated B cells after Ficoll centrifugation, the possible influence of 
contaminating beads on the binding of [3H]IL-2 was also tested: 18 #1 of packed 
beads (corresponding to a  50%  removal from cultured B blasts) were found to 
have no effect on the binding of [3H]IL-2 to nonactivated B or T  cells (data not 
shown). 
Next,  an  IL-2-binding curve  was  obtained  by incubating LPS plus anti-Ig- 
activated B  cells in  the presence of serial dilutions of [SH]IL-2 (Fig.  5A).  The 
Scatchard  plot  established  after  correcting  for  nonspecific  binding  (Fig.  5B) 
indicated that thus-activated B cells expressed -3,500 specific binding sites per 
cell  with  an  apparent  dissociation  constant  of  150  pM.  In  addition,  it  was 
confirmed that B cells activated by LPS alone did not specifically bind IL-2 (see 
Fig. 5A). 
Discussion 
This report shows that IL-2 is not only a  TCGF but also a  BCGF, that both 
activities  occur  at  very  similar  concentrations  of this  lymphokine,  and  that 
appropriately activated B  cells express  IL-2 receptors.  In particular,  it demon- 
strates that two independently derived human IL-2 preparations, i.e., recombi- 
nant IL-2 and immunoaffinity-purified IL-2, of apparent homogeneity and high 1178  INTERLEUKIN  2  IS  A  B CELL GROWTH  FACTOR 
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specific TCGF activity (1 U/per 0.3 ng protein, where 1 U/ml gives 50% maximal 
thymidine incorporation in the CTLL-2 assay), exhibited identical BCGF activity. 
It is, therefore, unlikely that contaminating substances caused the effects on B 
cells. It is also highly unlikely that the effect of IL-2 in the murine B blast assay 
using LPS plus anti-Ig-activated B cells was due to the IL-2-stimulated generation 
of other factors by contaminating T  cells (37). It was previously shown (25) that 
LPS plus anti-Ig-dependent B cell activation itself requires neither T  helper cells 
nor macrophages and, in the present study, T  cell contamination, not detectable 
by  the  FACS,  was  <0.3%  when  checked  by  immunohistochemical  analysis. 
Furthermore, a  variety of sources of T  cell factors, including total spleen cell 
SN, cloned T  helper cell SN (25), and T  hybridoma SN (13,  14, 23, 35), did not 
lead to stronger B cell proliferation than IL-2 alone.  In fact, there appeared a 
striking correlation between the IL-2 TCGF activity and the BCGF activity of 
all tested supernatants. P388Dl  SN had no effect in this assay. 
These results do not exclude the existence of BCGF distinct from IL-2. But, 
in providing more direct evidence than some previous studies (3, 4,  12-14,  23) 
for  the  functional  role  of IL-2  in  B  cell  responses,  the  data  raise  questions 
regarding the conclusions reached by many other authors (15-22,  37), i.e., that 
IL-2 has no BCGF activity. Several aspects need to be discussed: (a) There exists 
no  discrepancy  with  regard  to  the  experimental  data  themselves  in  that  the 
effects of IL-2 on LPS plus anti-Ig-activated murine B cells were previously not 
investigated.  It  is  thus possible  that  some  of the  previously described  factors 
participate (directly or via other cells) in B cell activation, whereas IL-2 would 
only act on appropriately activated B  cells.  Accordingly, it is conceivable that ZUBLER  ET  AL.  1179 
different "activation factors"  would  be detected in  different B  cell activation 
systems (16). (b) In addition, different types of BCGF could theoretically act on 
different subsets of B cells (16).  (c) Certain B cell lines may respond to other 
factors than activated normal  B cells (20,  38).  However, since most T  helper 
cells are capable of generating IL-2 (39), the demonstrated functional role of IL- 
2 in B cell proliferation is certainly relevant in the physiologic B cell response. 
In addition to the functional demonstration of the BCGF activity of IL-2, this 
study shows that LPS plus anti-lg-activated B cells express IL-2 receptors; i.e., 
the receptor assay using radiolabeled IL-2  indicated a  mean of 3,500  specific 
IL-2 binding sites per cell. It is known from limiting dilution analysis that in our 
system ~ 1 of 8  B cells become responsive to T  ceil-derived growth factors in 
the presence of LPS and anti-Ig (25). We assume that during 4 d of mass culture 
in the presence of EL-4 SN, these cells outgrow those that do not respond to IL- 
2, thereby generating a  homogeneous population with regard to IL-2 receptor 
expression.  However,  this  point  needs  further  investigation,  e.g.,  by  FACS 
analysis of the  proportion  of B  cells  bearing  IL-2  receptors,  using  anti-IL-2 
receptor antibody. In any case, in agreement with previous observations by Robb 
et  al.  (5),  B  cells activated  by  LPS  alone,  like  nonactivated  B  cells,  did  not 
significantly express IL-2 receptors. This also agrees with our previous finding 
(25) that anti-Ig is required for the induction of growth factor responsiveness of 
LPS-activated B cells. Whereas LPS plus anti-Ig-activated B cells expressed only 
two to  three times fewer IL-2  receptors than  we and others (5)  detected on 
activated normal murine T  cells, the receptor affinity was found to be five- (our 
unpublished data) to  ninefoid (5)  lower than that of such T  cells.  This  lower 
receptor affinity on B cells appears to contrast with the finding that B and T  cell 
proliferation required similar IL-2  concentrations, but  two points  need to  be 
discussed: (a) T  and B cells may differ with regard to the level of IL-2 receptor 
occupancy required  for cell  cycle progression,  and  (b)  the apparent  receptor 
affinity measured with binding assays may be influenced by complex variables, 
including the cell activation stage (i.e., culture conditions), receptor modulation, 
and possible heterogeneity of the receptors themselves. Until these variables are 
known, the value of 150 pM should be considered a minimal estimate of the IL- 
2 receptor affinity on activated B cells. 
A monoclonal antibody directed against the murine T  cell IL-2 receptor was 
previously found by Malek et al. (7) to react, although weakly, with LPS-activated 
B  cells.  Our  own studies in  progress show that another monoclonal antibody 
against the murine T  cell IL-2 receptor (obtained by Dr. M. Nabhoiz, Epalinges) 
inhibits B cell proliferation in an IL-2 dose-dependent way and that the radio- 
labeled antibody binds to LPS plus anti-Ig-activated B cells to almost the same 
extent as to Con A-activated normal T  cells (unpublished data). 
We  are  also  currently  investigating  the  effect  of  IL-2  on  human  B  cell 
proliferation. But, in confirmation of previous studies (14, 24-26, 40-42) show- 
ing that murine or human B cell activation normally requires a direct T-B cell 
interaction (alone or in conjunction with T-dependent antigens or anti-Ig), and 
because LPS does not bypass this T  helper signal in human B cell systems, we 
have thus far not obtained a T  cell-free human BCGF assay. Nonetheless, in an 
assay using irradiated mutant EL-4 thymoma cells, which provide an activation 1180  INTERLEUKIN 2  IS A B CELL GROWTH FACTOR 
signal(s)  to  murine  and  human  B  cells,  IL-2  optimally stimulated  murine  and 
human  B  cell  proliferation  (R.  Zubler,  C.  Mingari,  L.  Moretta,  and  H.  R. 
MacDonald, unpublished data). Thus, the previous observation that a monoclonal 
antibody reacting  with  the  human  T  cell  IL-2 receptor (6) did not react  with 
human B cells (43) could have been related to a suboptimal B cell activation.  In 
fact, it has been more recently (44) demonstrated that  this antibody (anti-Tac) 
recognizes on certain  human  B  tumor cells a  molecule of the size of the  IL-2 
receptor (44). 
Finally, we have observed (see Fig. 3) that IL°2 led to the generation of PFC 
in  the  murine  B blast assay.  However, the questions concerning  the nature  of 
the B cell differentiation signals in this assay and whether, in fact, differentiation 
signals are different from activation/proliferation  signals in the B cell response 
(45), were not addressed in this study. The Ig class/subclass distribution  of the 
PFC responses (46) remains to be studied in our systems. 
Summary 
In  this  study  we  investigated  whether  interleukin  2  (IL-2)  acts  on  B  cell 
proliferation  and  whether  activated  B  cells express  IL-2  receptors.  First,  the 
functional activity of immunoaffinity-purified or recombinant  human  IL-2 was 
studied in  a  B  blast assay using positively selected murine  surface  Ig-positive 
cells that had been activated by lipopolysaccharide (LPS) plus anti-Ig antibodies 
(anti-Ig).  In this assay, T  cells were not detected by fluorescence-activated cell 
sorter analysis.  It was found that  both IL-2 preparations  led to optimal  B  cell 
proliferation compared with supernatants obtained from murine or human spleen 
cells  or  murine  cloned  T  helper  cells.  Second,  we  observed  that  the  IL-2 
requirement  in  this assay was about the  same as in  a  proliferation  assay using 
lectin-activated polyclonal murine  Lyt-2-positive T  cells.  Third,  analysis of the 
binding of radiolabeled imunoaffinity-purified IL-2 to B cells indicated that LPS 
plus anti-Ig-activated  B cells expressed a mean of 3,500 IL-2 receptors per cell 
with an apparent dissociation constant of 150 pM. However, neither nonactivated 
B  cells  nor  B  cells activated  by  LPS alone  exhibited  significant  specific  IL-2 
binding. The functional and the receptor data are consistent with the conclusion 
that 1L-2 is a growth factor not only for T  cells but also for B cells. 
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Note added in proof'. Additional studies using very high [3H]IL-2 concentrations 
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receptors.  The  corresponding  mean  apparent  dissociation  constants  (~30  pM 
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